NAUT NAUTILUS BIOTECHNOLOGY INC

Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference

Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference

SEATTLE, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the TD Cowen 45th Annual Healthcare Conference.

Nautilus’ management is scheduled to participate in a fireside chat on Monday, March 3, 2025, at 1:50 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: .

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit .

Media Contact

Investor Contact



EN
18/02/2025

Underlying

NAUTNAUTILUS BIOTECHNOLOGY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NAUTILUS BIOTECHNOLOGY INC

 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual...

Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference SEATTLE, May 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the Goldman Sachs 46th Annual Global Healthcare Conference. Nautilus’ management is scheduled to participate in a fireside chat on Tuesday, June 10, 2025, at 2:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of t...

May 27, 2025 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology Reports First Quarter 2025 Financial Results

Nautilus Biotechnology Reports First Quarter 2025 Financial Results SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2025. “In Q1, we saw continued development progress based on the results of internal verification and validation work we’ve done on our Tau proteoform assay,” said Sujal Patel, CEO of Nautilus Biotechnology. “The assay’s reproducibility, accuracy, dynamic range, and sample compatibil...

April 29, 2025 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology to Announce First Quarter 2025 Financial Result...

Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025 SEATTLE, April 16, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today announced it will report financial results for the first quarter 2025 before market open on Tuesday, April 29, 2025. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the w...

April 16, 2025 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Fin...

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results SEATTLE, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2024. Reported total operating expenses for the fourth quarter of 2024 were $20.0 million, roughly equal to the fourth quarter of 2023, and $0.9 million above last quarter reflecting an ongoing focus on expense management;Announced an expectation...

February 27, 2025 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Heal...

Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference SEATTLE, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the TD Cowen 45th Annual Healthcare Conference. Nautilus’ management is scheduled to participate in a fireside chat on Monday, March 3, 2025, at 1:50 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “...

February 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch